

Appendix 5 (as supplied by the authors): Anaphylaxis and death reported among adults with allergic asthma or rhinitis

Author, year	Intervention	Anaphylaxis	Death
Allergic asthma			
No studies			
Allergic rhinitis			
CADTH 2014 ¹	SLIT v. placebo	"In study GT-14, five participants in the study drug group had anaphylactic reactions that were reported as probably being study drug related. One was considered of moderate severity and the remaining four were considered mild. Three participants were treated with epinephrine. All participants recovered from the event. No anaphylactic reaction was reported for the placebo group."	"In studies GT-08, P05238, and P08067, one death was reported in each study, as described below, but none were considered by the manufacturer to be treatment related."
Note: CI = confidence interval, NA = not assessed, NR = not reported, SCIT = subcutaneous immunotherapy, SLIT = sublingual immunotherapy, TEAE = treatment-emergent adverse event.			

Reference

1. CADTH. *Timothy grass standardized allergenic extract (Grastek - Merck Canada Inc.) Indication: allergic rhinitis (grass pollen)*. Health Technology Assessment Database; 2014.